Envelopes of retroviruses, including human immunodeficiency virus and simian immunodeficiency virus (SIV), contain host cell proteins that potentially represent novel targets for vaccine development. We show here that sera from rhesus macaques recognized simian major histocompatibility complex (MHC) molecules in response to infection with SIV. Antibodies from these animals did not cross-react with human MHC antigens on mitogen-activated peripheral blood mononuclear cells. The development of antibodies to MHC class I a-chain did not correlate with anti-SIV envelope antibody responses, suggesting that these antibodies did not arise through molecular mimicry. In contrast to the species-specific response in infected animals, sera from animals vaccinated with inactivated human cell-grown SIV reacted to both human and rhesus MHC class I and class II molecules.
Envelopes of immunodeficiency lentiviruses including human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) contain, in addition to virus-encoded glycoproteins, host cell membrane proteins, particularly molecules encoded by the major histocompatibility complex (MHC) (reviewed in Tremblay et al., 1998) . MHC molecules are present in virions at levels exceeding gp120/ gp41 (Henderson et al., 1987; Arthur et al., 1992) and are incorporated non-randomly (Hoxie et al., 1987; Poon et al., 2000; Nguyen & Hildreth, 2000) . Furthermore, it has been shown that incorporation of HLA-DR by clinical isolates of HIV-1 expanded in primary human cells depends on the producing cell and the donor source (Cantin et al., 2001) .
The influence of immune responses to virus-incorporated host cell antigens was dramatically illustrated when vaccination with uninfected human T-cells was shown to protect a proportion of macaques against challenge with human cellgrown SIV (Stott, 1991) . Furthermore, human cell-grown SIV and HIV inactivated virus vaccines conferred potent protection against systemic autologous and heterologous virus challenge and even against mucosal challenge (Cranage et al., 1992a) but only when the challenge virus was grown in human cells. Critically, no vaccine-induced protection was seen against SIV that had been grown in simian cells (Cranage et al., 1992b) . This xeno-immunization effect was correlated with antibody responses to human MHC class I antigens (Chan et al., 1992; Cranage et al., 1993) . A direct demonstration of the role of xeno-MHC molecules in this vaccine effect was the finding that a proportion of macaques were protected from challenge with human cell-grown SIV following immunization with purified human MHC class I (Chan et al., 1995) , class II or L-cells transfected with HLA-DR4 (Stott et al., 1994) . In the latter case it was shown that protective immunity could be passively transferred to naïve macaques.
Much less is known about the biological significance of virion-incorporated allogeneic host cell molecules, i.e. the situation arising in nature, and immune responses directed against these proteins; however, it is reasonable to assume that virion-incorporated molecules may influence virus pathogenesis including early entry events and activation of the immune system. This is evidenced by studies indicating that these molecules may maintain function after incorporation into virions (Rossio et al., 1995; Fortin et al., 1997; Cantin et al., 1997; Saifuddin et al., 1994) . Anti-lymphocyte antibodies have been associated with infection by HIV (Dorsett et al., 1985; Müller et al., 1994; Riera et al., 1992; Daniel et al., 1989; Ozturk et al., 1987) and it has been suggested that immune responses to regions of MHC homology within virus-encoded proteins may be involved in HIV-and SIV-induced pathology (Habeshaw, 1994; Kion & Hoffmann, 1991; Grassi et al., 1991) . Antibodies to MHC molecules during infection may arise therefore through recognition of virion-acquired host proteins and/or through molecular mimicry. In this study we have investigated the specificity of anti-cell antibody responses arising during SIV infection in comparison to those induced by vaccination with inactivatedhuman cell-grown virus.
Flow cytometry of concanavalin-A activated (10 mg ml 21 , 72 h) human and rhesus peripheral blood mononuclear cells (PBMC) revealed that sera from SIV-infected animals (n=7), taken at various times 3 to 18 weeks after infection, bound to rhesus but not to human cells (data not shown). In contrast, sera from animals vaccinated with human cellgrown SIV or HIV-1 (n=12) bound to cells from both species although preferentially to human cells, confirming previously reported results (Langlois et al., 1992; Bergmeier et al., 1994) . Sera from neither infected nor vaccinated animals competed the binding of labelled monoclonal antibodies (W6/32 and CR3/43) against species crossreactive monomorphic anti-MHC class I or class II antigens.
To determine directly the cell surface targets of the anti-cell antibodies and to investigate the molecular specificity of the differential antibody binding activity seen by flow cytometry, activated human and rhesus PBMC were surface labelled with biotin (Meier et al., 1992) and serum reactivity was determined by immunoprecipitation ( Fig. 1 ).
Sera from naïve animals or from animals infected with SIV were essentially unreactive with labelled membranes of human PBMC (Fig. 1a , tracks 1 and 2). Sera from vaccinated animals precipitated various proteins including species of 12, 32, 35 and 43 kDa (Fig. 1a , track 3) comigrating with proteins precipitated by antibodies to MHC class II (32 and 35 kDa; b-and a-chains respectively) and to HLA class I (12 and 43 kDa; b-and a-chains respectively) (Fig. 1a , tracks 4 and 5 respectively). These results were consistent with those described previously, following immunoprecipitation of unlabelled cell lysates followed by Western blotting and probing with MHC-specific labelled antibodies (Cranage et al., 1993) . In addition, the previous study revealed that sera from vaccinated macaques precipitated an 86 kDa dimer of the class I heavy chain detectable under non-reducing conditions. A biotinylated species of 86 kDa was detected in the present study but was not precipitated by the anti-class I monoclonal antibody.
In contrast to the results with human PBMC, when surfacelabelled rhesus PBMC were used, sera from SIV-infected macaques precipitated a range of proteins of relative molecular mass 47 to 25 kDa (Fig. 1b, track 2 ), corresponding to species precipitated by sera from vaccinated animals (Fig. 1b, track 3 ). In addition, sera from vaccinated animals precipitated proteins of 66, 60, 56 and 12 kDa. Sera from both infected and vaccinated macaques precipitated proteins that corresponded in migration to MHC class II and class I heavy chains (Fig. 1b , tracks 4 and 5 respectively).
Next, to confirm the specificity of sera for MHC molecules, non-labelled lysates of mitogen-activated PBMC were used in immunoprecipitation assays. Eluted products were separated by SDS-PAGE and the presence of MHC class I and class II antigens was determined on Western blots essentially as described previously (Cranage et al., 1993) . When blots of products eluted from human and rhesus PBMC were probed with anti-MHC class I antibody (HC10), sera from vaccinates were found to precipitate class I a-chain from either species, although the strongest signal was obtained with human antigen (Fig. 2a and b , track 4). In contrast, sera from SIV-infected animals precipitated MHC class I a-chain only from rhesus PBMC lysates (Fig. 2a, b, track 3) . Similar results were obtained for b 2 -microglobulin and confirmed by ELISA (data not shown). The MHC class I a-chain was usually detected as a doublet of relative molecular mass 43/45 kDa in both human and rhesus preparations. Similarly, when immunoprecipitated products were probed with anti-MHC class II (CR3/43) (Fig. 2c, d ), sera from vaccinates precipitated both human and rhesus class II (track 4) but sera from SIVinfected animals precipitated only rhesus MHC class II (track 3). Interestingly, vaccinate sera precipitated only the 31 kDa class II band. Sera from SIV-infected macaques precipitated both the 33 and 31 kDa class II band, although the relative intensity of the two bands was quite variable in different experiments.
Thus, in contrast to the cross-reactive antibody response induced by vaccination with inactivated virus, SIV-infected macaques had antibodies that specifically recognized macaque MHC but failed to recognize human MHC. We believe this to be the first report of a species-specific anti-MHC antibody response in SIV infection. Anti-lymphocyte antibody responses have been reported in virus infections including infection with HIV-1 but little is known about why they arise and their specificity. The species specificity of the reactivity shown here by flow cytometry and immunoprecipitation of surface labelled PBMC was surprising and was, at least in part, linked to recognition of MHC molecules. Anti-HLA antibodies arising in infection with HIV-1 have been attributed to molecular mimicry. Specifically, antibodies to the immunodominant C5 region of HIV-1 gp120 have been shown to cross-react with HLA class I on activated cells (De Santis et al., 1994) . Antibodies that crossreact with HIV-1 gp120 and HLA a-chains have been induced in persons vaccinated with experimental HIV-1 envelope vaccines (De Santis et al., 1993) and antibodies to MHC class II have been described in patients with AIDS (De La Barrera et al., 1987) . A common epitope between HIV-1 gp41 and HLA class II has been described and one third of sera tested from HIV-1 infected individuals at different stages of disease were found to react with gp41 and HLA class II-derived peptides as well as with native HLA class II molecules (Golding et al., 1989) .
To determine if anti-MHC responses were related to SIVspecific immune responses serial serum samples taken from seven macaques were analysed for the development of anti-rhesus MHC class I a-chain antibody responses and antibody responses to SIV structural components following infection with SIV (Table 1) . Pre-inoculation sera did not react with any of the antigens tested. Anti-MHC class I responses usually occurred by 1 month after infection and in three instances were detectable prior to an anti-SIV envelope response. In one animal (K8) the anti-class I response appeared in the absence of responses to SIV Gag p27 and SIV Env gp120. This animal was definitely infected with SIV as evidenced by virus isolation from PBMC and detection of proviral DNA by PCR. Although K8 failed to make a response to gp120 at any time following infection and had a delayed response to SIV gp41, the anti-class I response peaked between 3 and 7 months post-infection. In contrast, animal 3H had no detectable anti-class I response until 3 months after infection but had seroconverted to SIV antigens 1 to 2 months after infection. The lack of correlation between the appearance of the anti-MHC class I response and the appearance of anti-SIV responses suggests that molecular mimicry, at least for MHC class I, is unlikely. The possibility of molecular mimicry cannot be excluded absolutely. It is possible that precipitating anti-MHC antibodies appear before antibodies reactive on Western blots; however, this is not supported by the results from animal 3H where anti-SIV responses precede the anti-MHC class I antibody response. If molecular mimicry does occur then the species-specific recognition of MHC implies a close evolutionary relationship between virus cross-reactive Other hypotheses to explain our findings include: early immune dysregulation induced by infection with SIV leading to a breakdown of tolerance; massive destruction of lymphocytes leading to enhanced presentation of cellular components and presentation of altered or immature MHC molecules due to acquisition by newly synthesized virions. Whilst the acquisition of host cell molecules by HIV and SIV is well documented, little is known about the physical state of these molecules. There may be structural constraints imposed by the virion-encoded proteins leading to selectivity of host cell molecule incorporation. For example, incorporation of MHC class II may require association with gp41 and the incorporation of MHC class I is haplotype dependent (Poon et al., 2000) . This may, at least in part, explain the species specificity reported in the present study. Antibodies to other, as yet unidentified host cell proteins, seen in this study, may arise in a similar manner. It is known that in addition to MHC molecules immunodeficiency viruses can incorporate molecules such as complement control proteins (Saifuddin et al., 1995) and adhesion molecules that have significant species variability.
Do anti-MHC antibody responses have functional significance? Recently, it has been shown that human antibodies to MHC alloantigens mediate lysis and neutralization of HIV-1 primary isolates in the presence of complement (Spear et al., 2001) . Anti-MHC class I antibodies may also have a role in virus clearance through opsinization (Benkirane et al., 1994) . Although antibodies induced by alloimmunization with a B-lymphoblastoid cell line (B-LCL) failed to protect macaques against SIV infection (Polyanskaya et al., 1997) , the anti-MHC response induced was incomplete. In another study, immunization of macaques with allogeneic lymphocytes protected 50 % of animals challenged (E. J. Stott and others, personal communication) . The finding that infectionrelated antibodies recognize virion-acquired host cell proteins needs further investigation as this may suggest novel targets for anti-envelope vaccine design.
